TY  - JOUR
AU  - Burmester, Gerd R
AU  - Bykerk, Vivian P
AU  - Buch, Maya H
AU  - Tanaka, Yoshiya
AU  - Kameda, Hideto
AU  - Praestgaard, Amy
AU  - van Hoogstraten, Hubert
AU  - Fernandez-Nebro, Antonio
AU  - Huizinga, Thomas
PY  - 2022
DO  - 10.1093/rheumatology/keab676
UR  - http://hdl.handle.net/10668/19832
T2  - Rheumatology (Oxford, England)
AB  - Sarilumab, as monotherapy or in combination with conventional synthetic DMARDs, such as MTX, has demonstrated improvement in clinical outcomes in patients with RA. The primary objective of this post hoc analysis was to compare the efficacy of...
LA  - en
KW  - IL-6Ri
KW  - MOBILITY
KW  - MONARCH
KW  - combination with MTX
KW  - monotherapy
KW  - rheumatoid arthritis
KW  - sarilumab
KW  - Antibodies, Monoclonal, Humanized
KW  - Antirheumatic Agents
KW  - Arthritis, Rheumatoid
KW  - Drug Therapy, Combination
KW  - Fatigue
KW  - Humans
KW  - Methotrexate
KW  - Pain
KW  - Treatment Outcome
TI  - Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis.
TY  - research article
VL  - 61
ER  -